Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Dr-Reddy's-Laboratories"

12 News Found

USFDA completes inspection at Dr Reddy's Laboratories' Bollaram API unit
News | June 17, 2023

USFDA completes inspection at Dr Reddy's Laboratories' Bollaram API unit

The inspection closed with zero observations


Advent International announces the completion of the acquision of Suven Pharma
News | September 30, 2023

Advent International announces the completion of the acquision of Suven Pharma

New Board of Directors and management team at Suven Pharma also appointed


India grants Emergency Use Authorisation to Sputnik Light
News | February 07, 2022

India grants Emergency Use Authorisation to Sputnik Light

This is the ninth Covid-19 vaccine approved in India


Expert panel recommends Emergency Use Authorisation for Sputnik Light
News | February 05, 2022

Expert panel recommends Emergency Use Authorisation for Sputnik Light

The recommendations have been sent to the Drugs Controller General of India (DCGI) for the final approval


Dr Reddy’s launch Venlafaxine ER tablets in the US
Drug Approval | December 10, 2021

Dr Reddy’s launch Venlafaxine ER tablets in the US

The tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.


Dr Reddy’s launch valsartan tablets in the US market
Drug Approval | December 09, 2021

Dr Reddy’s launch valsartan tablets in the US market

Dr. Reddy's valsartan tablets, USP are available in 40 mg in bottle count size of 30, and 80 mg, 160 mg and 320 mg tablets in bottle count sizes of 90


Indian pharma CEOs bet big on innovation to achieve US $130 bn
News | November 23, 2021

Indian pharma CEOs bet big on innovation to achieve US $130 bn

While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation


Funding push to pharma R&D critical for unleashing next phase of growth
News | November 20, 2021

Funding push to pharma R&D critical for unleashing next phase of growth

The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation


Dr Reddys Laboratories  posts Q2FY22 PAT at Rs 992 Cr
News | November 01, 2021

Dr Reddys Laboratories posts Q2FY22 PAT at Rs 992 Cr

Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021


Dr Reddy’s Lab launches carmustine in the US market
Drug Approval | October 16, 2021

Dr Reddy’s Lab launches carmustine in the US market

The BiCNU brand and generic market had U.S. sales of approximately US $ 19.4 million MAT for the most recent twelve months ending in August 2021, according to IQVIA Health